TRODELVY IS DESIGNED TO WORK DIFFERENTLY THAN TRADITIONAL CHEMOTHERAPIES
What TRODELVY is made of
TRODELVY is a type of drug called an antibody-drug conjugate, or ADC for short. Unlike traditional chemotherapy, ADCs contain 3 parts: an antibody, an anti-cancer drug, and a linker.
Looks for a specific protein, in this case Trop-2, which is found to be overexpressed in many cancers, including breast cancer
B. Anti-cancer drug
B Anti-cancer drug
Kills cancer cells once they’re found
Connects the anti-cancer drug to the antibody
How TRODELVY is thought to attack TNBC tumors
Scientists discovered that patients with triple-negative breast cancer (TNBC) have tumor cells that more often contain the Trop-2 protein. TRODELVY binds to cells with Trop-2.
Information from laboratory studies suggest that this is how TRODELVY works. The clinical benefit of these observations is unknown.
The antibody in TRODELVY finds and sticks to the Trop-2 protein
Once attached, TRODELVY delivers an anti-cancer drug directly into the TNBC cells.
TRODELVY kills the TNBC cells from within.
Trodelvy is the first and only mTNBC treatment
to target THE Trop-2 PROTEIN